Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 92

1.

Continuous therapy with pamidronate, a potent bisphosphonate, in postmenopausal osteoporosis.

Reid IR, Wattie DJ, Evans MC, Gamble GD, Stapleton JP, Cornish J.

J Clin Endocrinol Metab. 1994 Dec;79(6):1595-9.

PMID:
7989461
2.

Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group.

Liberman UA, Weiss SR, Bröll J, Minne HW, Quan H, Bell NH, Rodriguez-Portales J, Downs RW Jr, Dequeker J, Favus M.

N Engl J Med. 1995 Nov 30;333(22):1437-43.

3.

Effects of prolonged bisphosphonate therapy and its discontinuation on bone mineral density in post-menopausal osteoporosis.

Orr-Walker B, Wattie DJ, Evans MC, Reid IR.

Clin Endocrinol (Oxf). 1997 Jan;46(1):87-92.

PMID:
9059563
4.

Differential action of pamidronate on trabecular and cortical bone in women with involutional osteoporosis.

Fromm GA, Vega E, Plantalech L, Galich AM, Mautalen CA.

Osteoporos Int. 1991 Jun;1(3):129-33.

PMID:
1790400
5.

Three monthly intravenous injections of ibandronate in the treatment of postmenopausal osteoporosis.

Thiébaud D, Burckhardt P, Kriegbaum H, Huss H, Mulder H, Juttmann JR, Schöter KH.

Am J Med. 1997 Oct;103(4):298-307.

PMID:
9382122
6.

Site-dependent bone mineral density response to oral pamidronate and calcium in postmenopausal osteoporosis: a preliminary report.

Barreira JC, Messina OD, Maldonado-Cocco JA, Roldan EJ.

Clin Rheumatol. 1997 Jun;16(4):346-52.

PMID:
9259247
7.

Role of oral pamidronate in preventing bone loss in postmenopausal women.

Lees B, Garland SW, Walton C, Ross D, Whitehead MI, Stevenson JC.

Osteoporos Int. 1996;6(6):480-5.

PMID:
9116394
8.

Intermittent oral disodium pamidronate in established osteoporosis: a 2 year double-masked placebo-controlled study of efficacy and safety.

Ryan PJ, Blake GM, Davie M, Haddaway M, Gibson T, Fogelman I.

Osteoporos Int. 2000;11(2):171-6.

PMID:
10793877
9.

Effects of 1 alpha-hydroxyvitamin D3 on lumbar bone mineral density and vertebral fractures in patients with postmenopausal osteoporosis.

Orimo H, Shiraki M, Hayashi Y, Hoshino T, Onaya T, Miyazaki S, Kurosawa H, Nakamura T, Ogawa N.

Calcif Tissue Int. 1994 May;54(5):370-6.

PMID:
8062152
10.

Treatment of postmenopausal osteoporosis with continuous daily oral alendronate in comparison with either placebo or intranasal salmon calcitonin.

Adami S, Baroni MC, Broggini M, Carratelli L, Caruso I, Gnessi L, Laurenzi M, Lombardi A, Norbiato G, Ortolani S, et al.

Osteoporos Int. 1993;3 Suppl 3:S21-7.

PMID:
8298199
11.

Three-year effectiveness of intravenous pamidronate versus pamidronate plus slow-release sodium fluoride for postmenopausal osteoporosis.

Morabito N, Gaudio A, Lasco A, Vergara C, Tallarida F, Crisafulli G, Trifiletti A, Cincotta M, Pizzoleo MA, Frisina N.

Osteoporos Int. 2003 Jul;14(6):500-6. Epub 2003 May 15.

PMID:
12750879
12.

Daily oral pamidronate in women and men with osteoporosis: a 3-year randomized placebo-controlled clinical trial with a 2-year open extension.

Brumsen C, Papapoulos SE, Lips P, Geelhoed-Duijvestijn PH, Hamdy NA, Landman JO, McCloskey EV, Netelenbos JC, Pauwels EK, Roos JC, Valentijn RM, Zwinderman AH.

J Bone Miner Res. 2002 Jun;17(6):1057-64.

13.

Pamidronate increases bone mineral density in women with postmenopausal or steroid-induced osteoporosis.

Cauza E, Etemad M, Winkler F, Hanusch-Enserer U, Partsch G, Noske H, Dunky A.

J Clin Pharm Ther. 2004 Oct;29(5):431-6. Erratum in: J Clin Pharm Ther. 2005 Feb;30(1):96. Hanusch-Enserer, H [corrected to Hanusch-Enserer, U].

PMID:
15482386
14.

Clodronate reduces vertebral fracture risk in women with postmenopausal or secondary osteoporosis: results of a double-blind, placebo-controlled 3-year study.

McCloskey E, Selby P, Davies M, Robinson J, Francis RM, Adams J, Kayan K, Beneton M, Jalava T, Pylkkänen L, Kenraali J, Aropuu S, Kanis JA.

J Bone Miner Res. 2004 May;19(5):728-36. Epub 2004 Jan 19.

15.
16.

The use of etidronate and calcium versus calcium alone in the treatment of postmenopausal osteopenia: results of three years of treatment.

Montessori ML, Scheele WH, Netelenbos JC, Kerkhoff JF, Bakker K.

Osteoporos Int. 1997;7(1):52-8.

PMID:
9102064
17.

Factors associated with bisphosphonate treatment failure in postmenopausal women with primary osteoporosis.

Cairoli E, Eller-Vainicher C, Ulivieri FM, Zhukouskaya VV, Palmieri S, Morelli V, Beck-Peccoz P, Chiodini I.

Osteoporos Int. 2014 Apr;25(4):1401-10. doi: 10.1007/s00198-014-2619-3. Epub 2014 Feb 8.

PMID:
24510095
18.
19.

Treatment of post-menopausal osteoporosis with a combination of growth hormone and pamidronate: a placebo controlled trial.

Erdtsieck RJ, Pols HA, Valk NK, van Ouwerkerk BM, Lamberts SW, Mulder P, Birkenhäger JC.

Clin Endocrinol (Oxf). 1995 Nov;43(5):557-65.

PMID:
8548940

Supplemental Content

Support Center